title: [Anti-NMDAR paraneoplastic encephalitis].
authors.affiliation: Inserm CIC 501, pôle pédiatrique NHE, CHU de Clermont-Ferrand, 1, place Lucie-et-Raymond-Aubrac, 63003 Clermont-Ferrand, France.
authors.forename: M
authors.initials: M
authors.lastname: Tapin
authors.affiliation: Service de psychiatrie, centre hospitaliers Moulins-Yzeure, 10, avenue du Général-de-Gaulle, BP 609, 03006 Moulins, France.
authors.forename: R
authors.initials: R
authors.lastname: Faucher
authors.affiliation: Inserm CIC 501, pôle pédiatrique NHE, CHU de Clermont-Ferrand, 1, place Lucie-et-Raymond-Aubrac, 63003 Clermont-Ferrand, France.
authors.forename: V
authors.initials: V
authors.lastname: Poirier
authors.affiliation: Service de gynécologie-obstétrique, CHU de Clermont-Ferrand, Clermont-Ferrand, France.
authors.forename: S
authors.initials: S
authors.lastname: Curinier
authors.affiliation: Inserm CIC 501, pôle pédiatrique NHE, CHU de Clermont-Ferrand, 1, place Lucie-et-Raymond-Aubrac, 63003 Clermont-Ferrand, France. Electronic address: e_merlin@chu-clermontferrand.fr.
authors.forename: E
authors.initials: E
authors.lastname: Merlin
mesh_terms: D000293:Adolescent; D060426:Anti-N-Methyl-D-Aspartate Receptor Encephalitis / Q000175:diagnosis* / Q000188:drug therapy; D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use; D020363:Limbic Encephalitis / Q000175:diagnosis* / Q000188:drug therapy; D010051:Ovarian Neoplasms / Q000175:diagnosis* / Q000628:therapy; D016194:Receptors, N-Methyl-D-Aspartate / Q000276:immunology; D000069283:Rituximab; D013724:Teratoma / Q000175:diagnosis* / Q000628:therapy
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D007155:Immunologic Factors; D016194:Receptors, N-Methyl-D-Aspartate; D000069283:Rituximab; D003520:Cyclophosphamide